Dancing With DPP-1: The Inflammatory Tango of Bronchiectasis

Grant W Waterer¹, Sanjay H Chotirmall^{2

3}

Affiliations

¹ University of Western Australia, Medicine, Perth, Western Australia, Australia.
² Lee Kong Chian School of Medicine, Translational Respiratory Research Laboratory, Singapore, Singapore.
³ Singapore; schotirmall@ntu.edu.sg.

Grant W Waterer et al. Am J Respir Crit Care Med. 2025.

. 2025 Feb 18;211(5):678-679.

doi: 10.1164/rccm.202501-0032ED. Online ahead of print.

Grant W Waterer¹, Sanjay H Chotirmall^{2

3}

¹ University of Western Australia, Medicine, Perth, Western Australia, Australia.
² Lee Kong Chian School of Medicine, Translational Respiratory Research Laboratory, Singapore, Singapore.
³ Singapore; schotirmall@ntu.edu.sg.

No abstract available

Comment on

1. Chotirmall SH, Chalmers JD. The precision medicine era of bronchiectasis. Am J Respir Crit Care Med . 2024;210:24–34. - PMC - PubMed
1. Waterer GW. What changes in research focus do we need to advance care for patients with bronchiectasis? Am J Respir Crit Care Med . 2024;210:22–23. - PMC - PubMed
1. Shteinberg M, Waterer G, Chotirmall SH. A global effort to stop the vicious vortex: a special American Journal of Respiratory and Critical Care Medicine issue for World Bronchiectasis Day 2024. Am J Respir Crit Care Med . 2024;210:1–3. - PMC - PubMed
1. Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, et al. WILLOW Investigators Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med . 2020;383:2127–2137. - PubMed
1. Metersky M, Burgel PR, Daley CL, Soyza A, Haworth CS, Mauger D, et al. Annualized exacerbation rate in patients with non-cystic fibrosis bronchiectasis by prespecified subgroups in the PH3, randomized, double-blind, placebo-controlled ASPEN trial [abstract] Chest . 2024;166:A6554–A6556.